



Dear contributors, colleagues and co-workers,

In the midst of the “second wave” of the covid-19 pandemic, I wish to give you another update on the SENOMAC trial. Until November 10, we had together randomised **2188 patients** (see following figures) despite a slight decline in Swedish inclusion rates. Many of us have reported significantly lower numbers of new breast cancer cases at our clinics, which is mirrored in the trial, but we expect figures to rise again once routine care can regain ground.




The new version of the trial protocol (version 8.1) has gone through most international sites' ethics committees now. Currently, some new sites have been started up in Italy and Greece, and further sites in Austria and Germany will open soon. We are currently analysing data on arm morbidity after one year in the first 1000 patients and will report results as soon as they are available. Furthermore, Swedish and Danish radiotherapy plans have been collected now and are assessed regarding validity of data in the eCRF and dose distribution to axillary levels. Results of this quality control will be available in spring 2021.

In May, we will have the next safety analysis and before that, we will contact you all in order to update follow-up data as much as possible in good time.

Please do remember that any regional nodal recurrence mandates a computed tomography in order to define the affected axillary level(s).

I thank you all for your efforts for the SENOMAC trial despite covid-related changes and adjustments in breast cancer care. Please also have a look at the following table and figure, and share this newsletter with your colleagues and co-workers.

My best wishes for a peaceful and healthy Christmas period,



Jana de Boniface,  
for the SENOMAC steering committee and the sponsor Karolinska Institutet.  
[jana.de-boniface@ki.se](mailto:jana.de-boniface@ki.se) or [jana.de-boniface@capiostgoran.se](mailto:jana.de-boniface@capiostgoran.se)

Table: Number of site-specific randomisations as of **November 10, 2020**

**Please observe that this table only shows those sites that have generated randomisations as of 2020NOV10. For a list of all initiated sites, please see the trial homepage.**

Site	Country	Initiation visit	First patient in	Number of randomisations
Karolinska	Sweden	2015-01-30	2015-02-27	111
Västerås	Sweden	2015-03-02	2015-04-14	52
S:t Göran	Sweden	2015-03-05	2016-06-07	170
Akademiska Uppsala	Sweden	2015-03-12	2016-02-14	47
Södersjukhuset	Sweden	2015-03-18	2015-11-24	122
Örebro	Sweden	2015-03-25	2015-10-01	51
Sahlgrenska	Sweden	2015-04-23	2015-06-10	103
Lund/Malmö	Sweden	2015-05-13	2015-10-13	111
Helsingborg	Sweden	2015-05-20	2015-07-23	47
Linköping	Sweden	2015-05-27	2016-11-03	94
Karlstad	Sweden	2015-05-28	2015-12-14	39
Lidköping/Skövde	Sweden	2015-06-04	2015-10-22	77
Uddevalla	Sweden	2015-06-04	2015-09-21	24
Kalmar	Sweden	2015-09-02	2016-03-03	16
Västervik	Sweden	2015-09-02	2016-02-18	31
Karlskrona	Sweden	2015-09-03	2015-12-14	8
Gävle	Sweden	2015-09-10	2015-12-30	39
Sundsvall	Sweden	2015-10-15	2015-10-29	57
Umeå	Sweden	2015-11-19	2016-02-10	53
Halmstad/Varberg	Sweden	2015-12-10	2016-02-17	29
Växjö	Sweden	2016-01-14	2016-03-23	37
Aarhus	Denmark	2016-11-28	2017-04-25	102
Randers	Denmark	2017-09-14	2017-11-07	18
Köpenhamn Rigshospitalet/Herlev	Denmark	2016-12-19	2017-04-20	221
Jönköping	Sweden	2017-01-20	2017-11-13	38
Kristianstad	Sweden	2017-03-20	2017-05-17	40
Borås	Sweden	2017-02-20	2018-09-14	8
Aabenraa	Denmark	2017-10-12	2017-12-13	64
Odense	Denmark	2017-11-22	2018-02-16	44
Esbjerg	Denmark	2017-12-12	2018-03-05	12
Viborg	Denmark	2017-11-03	2018-03-16	71
Aalborg	Denmark	2017-10-10	2018-02-07	77
Bad Langensalza	Germany	2018-04-04	2018-05-23	4
Rostock	Germany	2018-03-12	2018-06-07	11
Berlin Spandau	Germany	2018-04-19	2018-09-07	4
Laiko 1, Athens	Greece	2018-06-28	2018-10-12	12

Vejle	Danmark	2018-03-19	2018-11-07	49
Esslingen	Germany	2018-02-16	2018-10-26	2
Klinikum Kassel	Germany	2018-06-12	2018-11-22	1
Heraklion, Crete	Greece	2019-02-19	2019-03-07	9
Athens Euroclinic	Greece	2019-12-11	2019-02-12	5
Dresden	Germany	2018-05-02	2019-03-01	6
Hanau	Germany	2018-05-18	2019-02-12	8
Karlsruhe	Germany	2018-07-11	2018-12-18	1
Villingen-Schwenningen	Germany	2018-09-10	2018-12-28	1
Mittelbaden	Germany	2018-08-16	2019-03-13	3
Laiko 2, Athens	Greece	2018-11-07	2019-05-29	4
San Raffaele Milano	Italy	2018-02-01	2019-05-21	4
IEO Milano	Italy	2019-05-06	2019-06-06	20
Unna	Germany	2018-03-01	2019-05-28	5
Ebersberg	Germany	2018-04-10	2019-04-06	2
Stendal	Germany	2018-04-25	2019-05-14	1
Wiesbaden St. Josef	Germany	2018-06-14	2019-05-03	1
Worms	Germany	2018-08-28	2019-05-02	2
Potsdam	Germany	2019-06-18	2019-07-01	4
Tübingen	Germany	2019-09-04	2019-09-24	6
Böblingen	Germany	2018-07-10	2019-11-07	2
Wiesbaden Asklepios	Germany	2019-11-27	2020-01-28	2
Dresden St Joseph	Germany	2019-10-08	2020-05-18	1
Bochum	Germany	2018-02-07	2020-05-05	4
Helena Venizelou	Greece	2020-07-30	2020-09-18	1
<b>Total</b>				<b>2188</b>

Figure: Accumulated site-specific inclusion (only sites generating randomisations as of **November 10, 2020** are shown).

